FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130584549> ?p ?o ?g. }

• W2130584549 endingPage "609" @default.
• W2130584549 startingPage "598" @default.
• W2130584549 abstract "Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhibitor resistance were enrolled; 17 of 39 patients (44%) had tumor shrinkage, with 5 patients (13%) achieving partial response. Pharmacodynamic studies confirmed marked Sym004-induced EGFR downmodulation. MET gene amplification emerged in 1 patient during Sym004 treatment, and a partial response was seen in a patient with EGFR(S492R) mutation that is predictive of cetuximab resistance.Potent EGFR downmodulation with Sym004 in patients with metastatic colorectal cancer and acquired resistance to cetuximab/panitumumab translates into significant antitumor activity and validates the preclinical hypothesis that a proportion of tumors remains dependent on EGFR signaling. Further clinical development and expanded correlative analyses of response patterns with secondary RAS/EGFR mutations are warranted." @default.
• W2130584549 created "2016-06-24" @default.
• W2130584549 creator A5013825576 @default.
• W2130584549 creator A5015190461 @default.
• W2130584549 creator A5024569067 @default.
• W2130584549 creator A5030825777 @default.
• W2130584549 creator A5031770911 @default.
• W2130584549 creator A5037467265 @default.
• W2130584549 creator A5040154466 @default.
• W2130584549 creator A5042918352 @default.
• W2130584549 creator A5048677914 @default.
• W2130584549 creator A5051105658 @default.
• W2130584549 creator A5053880366 @default.
• W2130584549 creator A5055862157 @default.
• W2130584549 creator A5060992997 @default.
• W2130584549 creator A5062966348 @default.
• W2130584549 creator A5069313460 @default.
• W2130584549 creator A5070570779 @default.
• W2130584549 creator A5087015760 @default.
• W2130584549 creator A5090645179 @default.
• W2130584549 creator A5091727687 @default.
• W2130584549 date "2015-06-01" @default.
• W2130584549 modified "2023-10-11" @default.
• W2130584549 title "Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer" @default.
• W2130584549 cites W1544959878 @default.
• W2130584549 cites W1932563524 @default.
• W2130584549 cites W1967295501 @default.
• W2130584549 cites W1972612242 @default.
• W2130584549 cites W1997681258 @default.
• W2130584549 cites W2006168411 @default.
• W2130584549 cites W2019607817 @default.
• W2130584549 cites W2030733555 @default.
• W2130584549 cites W2062109911 @default.
• W2130584549 cites W2083802683 @default.
• W2130584549 cites W2085633477 @default.
• W2130584549 cites W2095201384 @default.
• W2130584549 cites W2098354753 @default.
• W2130584549 cites W2106789440 @default.
• W2130584549 cites W2108516575 @default.
• W2130584549 cites W2116731538 @default.
• W2130584549 cites W2133520792 @default.
• W2130584549 cites W2136269414 @default.
• W2130584549 cites W2137950260 @default.
• W2130584549 cites W2141630197 @default.
• W2130584549 cites W2143911880 @default.
• W2130584549 cites W2149782431 @default.
• W2130584549 cites W2155311724 @default.
• W2130584549 cites W2158819778 @default.
• W2130584549 cites W2161479438 @default.
• W2130584549 cites W2163799638 @default.
• W2130584549 cites W2170552969 @default.
• W2130584549 cites W3184738567 @default.
• W2130584549 doi "https://doi.org/10.1158/2159-8290.cd-14-1432" @default.
• W2130584549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25962717" @default.
• W2130584549 hasPublicationYear "2015" @default.
• W2130584549 type Work @default.
• W2130584549 sameAs 2130584549 @default.
• W2130584549 citedByCount "67" @default.
• W2130584549 countsByYear W21305845492015 @default.
• W2130584549 countsByYear W21305845492016 @default.
• W2130584549 countsByYear W21305845492017 @default.
• W2130584549 countsByYear W21305845492018 @default.
• W2130584549 countsByYear W21305845492019 @default.
• W2130584549 countsByYear W21305845492020 @default.
• W2130584549 countsByYear W21305845492021 @default.
• W2130584549 countsByYear W21305845492022 @default.
• W2130584549 countsByYear W21305845492023 @default.
• W2130584549 crossrefType "journal-article" @default.
• W2130584549 hasAuthorship W2130584549A5013825576 @default.
• W2130584549 hasAuthorship W2130584549A5015190461 @default.
• W2130584549 hasAuthorship W2130584549A5024569067 @default.
• W2130584549 hasAuthorship W2130584549A5030825777 @default.
• W2130584549 hasAuthorship W2130584549A5031770911 @default.
• W2130584549 hasAuthorship W2130584549A5037467265 @default.
• W2130584549 hasAuthorship W2130584549A5040154466 @default.
• W2130584549 hasAuthorship W2130584549A5042918352 @default.
• W2130584549 hasAuthorship W2130584549A5048677914 @default.
• W2130584549 hasAuthorship W2130584549A5051105658 @default.
• W2130584549 hasAuthorship W2130584549A5053880366 @default.
• W2130584549 hasAuthorship W2130584549A5055862157 @default.
• W2130584549 hasAuthorship W2130584549A5060992997 @default.
• W2130584549 hasAuthorship W2130584549A5062966348 @default.
• W2130584549 hasAuthorship W2130584549A5069313460 @default.
• W2130584549 hasAuthorship W2130584549A5070570779 @default.
• W2130584549 hasAuthorship W2130584549A5087015760 @default.
• W2130584549 hasAuthorship W2130584549A5090645179 @default.
• W2130584549 hasAuthorship W2130584549A5091727687 @default.
• W2130584549 hasBestOaLocation W21305845491 @default.
• W2130584549 hasConcept C121608353 @default.
• W2130584549 hasConcept C126322002 @default.
• W2130584549 hasConcept C143998085 @default.
• W2130584549 hasConcept C151730666 @default.
• W2130584549 hasConcept C2777506169 @default.
• W2130584549 hasConcept C2778332735 @default.
• W2130584549 hasConcept C2779343474 @default.
• W2130584549 hasConcept C2779438470 @default.
• W2130584549 hasConcept C2779998722 @default.
• W2130584549 hasConcept C502942594 @default.

• next